SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BofA Securities Initiates Viridian Therapeutics Coverage With Buy Rating

BofA Securities initiated coverage of Viridian Therapeutics with a Buy rating and a $47 price target.

VRDN

Related stories